Human organoids in basic research and clinical applications.

Tang XY, Wu S, Wang D, Chu C, Hong Y, Tao M, Hu H, Xu M, Guo X, Liu Y. · 2022

Read Human organoids in basic research and clinical applications. by Tang XY, Wu S, Wang D, Chu C, Hong Y, Tao M, Hu H, Xu M, Guo X, Liu Y. (2022) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc9127490.txt.

Introduction

Tang and co-authors update progress on human organoids for basic research and clinical use. Organoids are tiny three-dimensional structures grown in the lab from stem cells. They mimic the cell mix, shape, and jobs of real organs. Organoids from patients also carry that person's genetic makeup.

The update covers methods for growing brain, retinal, kidney, liver, lung, gut, and heart organoids. It compares organoids from pluripotent stem cells with those from adult stem cells. Uses span disease study, drug testing, gene repair, and transplant work. The authors also name current limits that hold the field back. Readers get a broad guide to a tool that brings human biology into the dish.

Catalog record

CREATORTang XY, Wu S, Wang D, Chu C, Hong Y, Tao M, Hu H, Xu M, Guo X, Liu Y.
YEAR2022
COLLECTIONPAPERS
FORMATTXT
FILE SIZE118 KB
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC9127490

Browse the full library · About the Tower of Babel

Full text

The opening of the work, from the library's hosted text:

Human organoids in basic research and clinical applications By Xiao-Yan Tang, Shanshan Wu, Da Wang, Chu Chu, Yuan Hong, Mengdan Tao, Hao Hu, Min Xu, Xing Guo, Yan Liu Published in: Signal Transduction and Targeted Therapy DOI: 10.1038/s41392-022-01024-9 ABSTRACT Abstract Organoids are three-dimensional (3D) miniature structures cultured in vitro produced from either human pluripotent stem cells (hPSCs) or adult stem cells (AdSCs) derived from healthy individuals or patients that recapitulate the cellular heterogeneity, structure, and functions of human organs. The advent of human 3D organoid systems is now possible to allow remarkably detailed observation of stem cell morphogens, maintenance and differentiation resemble primary tissues, enhancing the potential to study both human physiology and developmental stage. As they are similar to their original organs and carry human genetic information, organoids derived from patient hold great promise for biomedical research and preclinical drug testing and is currently used for personalized, regenerative medicine, gene repair and transplantation therapy. In recent decades, researchers have succeeded in generating various types of organoids mimicking in vivo organs. Herein, we provide an update on current in vitro differentiation technologies of brain, retinal, kidney, liver, lung, gastrointestinal, cardiac, vascularized and multi-lineage organoids, discuss the differences between PSC- and AdSC-derived organoids, summarize the potential applications of stem cell-derived organoids systems in the laboratory and clinic, and outline the current challenges for the application of organoids, which would deepen the understanding of mechanisms of human development and enhance further utility of organoids in basic research and clinical studies. Subject terms: Stem-cell differentiation, Regeneration INTRODUCTION Animal models and two-dimensional (2D) cell lines have been successfully applied in biomedical fields over the past 100 years for purposes such as improving our knowledge of cellular signaling pathways, developing guidelines for the design of candidate compounds, identifying potential drug targets, and clarifying the underlying pathological mechanisms of diseases. The value of the model systems is evidenced by the widespread use of these systems worldwide in biomedical research today. However, species differences between animals and humans have become major obstacles for the application of animal models in drug discoveries. The main disadvantage of 2D cell lines is their lack of hierarchical structure, dimensionality, cellular diversity, and cell–cell or cell–matrix interactions, which prevents the cell lines from mimicking the cellular functions present in tissues. Tissue explants may transiently capture physiologically relevant cell organization and interactions, but they are difficult to maintain for long periods of time in vitro due to rapid phenotype disappearance.1 Learning human genetic diversity and figuring out its impact on disease pathogeneses and drug responses is vital for the achievement of personalized medicine. Hence, it is important to optimize biological systems in order to eliminate the gap between the cellular and organ levels that is present in most current model systems. The advent of human pluripotent stem cell (PSC) technology and adult stem cell (AdSC; also known as tissue stem cell) culture systems has opened an avenue for the establishment of in vitro human-specific models for the study of genetic variants associated with human disease and the generation of cellular materials on large-scale compound screening. The first human pluripotent stem cell line, a line of human embryonic stem cells (ESCs), was established in 1998,2 almost two decades after the exploration of mouse pluripotent cell lines reported in 1981.3,4 Thereafter, Kazutoshi Takahashi and Shinya Yamanaka reprogrammed mouse fibroblast cells to become PSCs in 2006 by inserting four transcription factors encoding genes Oct4, Sox2, Klf4, and c-Myc. These cells, which were similar to ESCs with regard to their gene expression and potential to develop into three germ layers, were termed induced PSCs (iPSCs). Human iPSC (hiPSC) technology was first established in 20075,6 and has been widely used to generate human “disease-in-a-dish” models. This technology may enable personalized disease modeling that will become an important part of precision medicine. Furthermore, the development of clustered regulatory interspaced short palindromic repeat (CRISPR)/Cas9 endonuclease7–9 enabled the creation of genetically edited hiPSC-based disease models. Early approaches focused on iPSC-derived 2D cell cultures, which often lack cell–cell interactions, diversity and microcircuits. Recently, the emergence of in vitro human three-dimensional (3D) organ culture approaches has received widespread attention because it allows more complex organ-like structures and different cell types to be modeled simultaneously. 3D organoids derived from primary tissues, ESCs or iPSCs can self-renew, and self-organize, and exhibit multicellularity and functionality similar to those of in vivo organs. The “organoid” was first reported in oncology as a synonym of “teratoma”, as first reported in 1946.10 In the 1960s, “organoids” were used to describe organogenesis by cell dissociation and reaggregation experiments performed by developmental biologists.11 Previous studies have harnessed the ability of 3D self-organizing from primary tissues, and improvements in organoid systems in the stem cell field were triggered by the establishment of an intestinal organoid culture system in 2009.12 Unlike previous systems, these new methods provided a stable system that could sustain the long-term culture of epithelial-like cells from sorted Lgr5+ stem cells or dissected crypts by providing in vivo intestinal stem cell niche components, including epidermal growth factor (EGF), Noggin, and R-spondin-1, and embedded in Matrigel to promote expansion.12 Notably, these organoids largely reproduced the tissue architecture in vivo and contained a relatively intact complement of stem cells, progenitor cells, and terminally differentiated cell types. By modifying the combination of growth factors and cell isolation procedures, researchers can rapidly alter the 3D culture system to generate multiple kinds of human normal and cancerous organoids, such as brain,13,14 colon,15 stomach,16 and liver organoids.17,18 In this review, we discuss recent advances in organoid technologies and describe the main classes of organoids. We critically evaluate their potential applications value in basic biology, disease modeling, therapeutic screening, regenerative medicine, and others. We also highlight existing limitations or challenges that remain to be overcome. ORGANOIDS FROM PSCS AND ADSCS Both PSC- and AdSC-derived organoids can form 3D organ-like aggregates to recapitulate the in vivo architecture and function of organs, to some extent. However, there are still some differences between organs and organoids. Zhang et al. firstly generated hPSC-derived spheroids to induce the differentiation of neural lineages and reconstruct neural tube structures in vitro.19,20 PSC-derived brain organoid-like spheroids were first reported in 2008 by Sasai’s group and then other organoids were generated from PSCs21–25 (Fig. 1). To date, many researchers have established different step-by-step schemes of generating organoids from PSCs; however, these protocols generally take several months, and specific cocktails of growth factors need to be added at each step. Patient-derived somatic cells were first reprogrammed into iPSCs, which then expanded and finally differentiated into specific tissue cell types. PSC-derived organoids usually lose their ability to further expand once the cells reach the time point of terminal differentiation. Due to the pluripotency of PSCs, the cellular components in PSC-derived organoids are relatively complex, including mesenchymal, epithelial and even endothelial components.26,27 Thus, PSC-derived organoids are more suitable for studying early organogenesis in human developmental biology because their forming process only occur during embryonic development.28 Correspondingly, AdSC-derived organoids were first reported in 2009 for the intestine after identifying small intestinal stem cells by Clevers’ group.12,29 Compared with PSC-derived organoids, AdSC-derived organoids are directly obtained from regenerative human adult tissues with a simpler procedure in less time27,30 (Fig. 2). The

Read the complete text